← Back to headlines
Arbutus Biopharma's Lead Asset Granted FDA Fast Track Status
Arbutus Biopharma announced that its lead drug candidate has received Fast Track designation from the U.S. Food and Drug Administration (FDA).
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
